EA201590888A1 - Мутации флавивирусного белка оболочки, нарушающие разборку вириона - Google Patents

Мутации флавивирусного белка оболочки, нарушающие разборку вириона

Info

Publication number
EA201590888A1
EA201590888A1 EA201590888A EA201590888A EA201590888A1 EA 201590888 A1 EA201590888 A1 EA 201590888A1 EA 201590888 A EA201590888 A EA 201590888A EA 201590888 A EA201590888 A EA 201590888A EA 201590888 A1 EA201590888 A1 EA 201590888A1
Authority
EA
Eurasian Patent Office
Prior art keywords
mutations
viryon
disorder
breaking
protein protection
Prior art date
Application number
EA201590888A
Other languages
English (en)
Inventor
Владимир Ямщиков
Original Assignee
Саутерн Рисерч Инститьют
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Саутерн Рисерч Инститьют filed Critical Саутерн Рисерч Инститьют
Publication of EA201590888A1 publication Critical patent/EA201590888A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • C12N2770/24162—Methods of inactivation or attenuation by genetic engineering
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Credit Cards Or The Like (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Mycology (AREA)

Abstract

В центральный контактный интерфейс мономеров флавивирусного белка оболочки введены мутации, которые модулируют инфекционность флавивируса. Мутации уменьшают способность димерного белка оболочки диссоциировать.
EA201590888A 2012-11-07 2013-11-06 Мутации флавивирусного белка оболочки, нарушающие разборку вириона EA201590888A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/671,111 US9267114B2 (en) 2012-11-07 2012-11-07 Flavivirus envelope protein mutations affecting virion disassembly
PCT/US2013/068616 WO2014074535A2 (en) 2012-11-07 2013-11-06 Flavivirus envelope protein mutations affecting virion disassembly

Publications (1)

Publication Number Publication Date
EA201590888A1 true EA201590888A1 (ru) 2016-02-29

Family

ID=50622575

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201590888A EA201590888A1 (ru) 2012-11-07 2013-11-06 Мутации флавивирусного белка оболочки, нарушающие разборку вириона

Country Status (9)

Country Link
US (1) US9267114B2 (ru)
EP (1) EP2916865A4 (ru)
JP (1) JP2015535302A (ru)
CN (1) CN104918635A (ru)
AU (1) AU2013341356A1 (ru)
CA (1) CA2890406A1 (ru)
EA (1) EA201590888A1 (ru)
MX (1) MX2015005808A (ru)
WO (1) WO2014074535A2 (ru)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201413086D0 (en) 2014-07-23 2014-09-03 Imp Innovations Ltd And Inst Pasteur Methods
US11364292B2 (en) 2015-07-21 2022-06-21 Modernatx, Inc. CHIKV RNA vaccines
US11007260B2 (en) 2015-07-21 2021-05-18 Modernatx, Inc. Infectious disease vaccines
CN105087607A (zh) * 2015-09-28 2015-11-25 山东出入境检验检疫局检验检疫技术中心 鸭坦布苏病毒e蛋白第三结构域原核表达的方法及其应用
AU2016335120A1 (en) 2015-10-07 2018-05-24 The University Of North Carolina At Chapel Hill Methods and compositions for dengue virus vaccines and diagnostistics
WO2017070624A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Tropical disease vaccines
EP3184119A1 (en) 2015-12-23 2017-06-28 Themis Bioscience GmbH Chromatography based purification strategies for measles scaffold based viruses
US20170354729A1 (en) * 2016-03-16 2017-12-14 Novavax, Inc. Vaccine compositions containing modified zika virus antigens
WO2018022790A1 (en) * 2016-07-27 2018-02-01 Hawaii Biotech Inc. Optimized zika virus envelope gene and expression thereof
WO2018071405A1 (en) * 2016-10-11 2018-04-19 University Of Miami Vectors and vaccine cells for immunity against zika virus
KR102511472B1 (ko) * 2016-11-28 2023-03-16 메디젠, 인크. 양성 가닥 rna 바이러스에 의해 유발되는 감염성 질환에 대한 백신
EP3582790A4 (en) 2017-02-16 2020-11-25 ModernaTX, Inc. VERY POWERFUL IMMUNOGENIC COMPOSITIONS
US10653767B2 (en) 2017-09-14 2020-05-19 Modernatx, Inc. Zika virus MRNA vaccines
WO2020190750A1 (en) 2019-03-15 2020-09-24 Modernatx, Inc. Hiv rna vaccines
CN114807232A (zh) * 2022-05-12 2022-07-29 中国人民解放军海军军医大学 一株西尼罗病毒感染性克隆的构建及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040031072A1 (en) 1999-05-06 2004-02-12 La Rosa Thomas J. Soy nucleic acid molecules and other molecules associated with transcription plants and uses thereof for plant improvement
US20110131679A2 (en) 2000-04-19 2011-06-02 Thomas La Rosa Rice Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement
US7214786B2 (en) 2000-12-14 2007-05-08 Kovalic David K Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement
US20050002968A1 (en) 2002-01-15 2005-01-06 Monath Thomas P. Flavivirus vaccines
JP4683926B2 (ja) 2002-11-15 2011-05-18 サノフィ パスツール バイオロジクス カンパニー ウエストナイルウイルス・ワクチン
WO2005042014A1 (en) 2003-10-29 2005-05-12 The University Of Queensland West nile virus vaccine
US7459163B2 (en) 2004-02-25 2008-12-02 University Of Kansas Infectious DNA as a vaccine against west nile and other flaviviruses
CA2584228C (en) * 2004-10-20 2015-05-05 Acambis Inc. Vaccines against japanese encephalitis virus and west nile virus
US7455842B2 (en) 2005-12-05 2008-11-25 University Of Kansas Chimeric West Nile viruses and uses thereof
EP2002036A4 (en) 2006-03-09 2010-01-27 Univ Texas COMPOSITIONS AND METHODS RELATING TO THE PROFILING OF MULTIPLE CELL LINES ON PEPTIDE BONDING BASIS
US9868781B2 (en) 2008-06-02 2018-01-16 Cornell University Antibodies for ubiquitinated proteins

Also Published As

Publication number Publication date
JP2015535302A (ja) 2015-12-10
WO2014074535A3 (en) 2014-07-17
EP2916865A4 (en) 2016-05-25
WO2014074535A2 (en) 2014-05-15
US9267114B2 (en) 2016-02-23
AU2013341356A1 (en) 2015-05-21
EP2916865A2 (en) 2015-09-16
WO2014074535A9 (en) 2014-09-04
CN104918635A (zh) 2015-09-16
US20140127261A1 (en) 2014-05-08
CA2890406A1 (en) 2014-05-15
MX2015005808A (es) 2016-02-25

Similar Documents

Publication Publication Date Title
EA201590888A1 (ru) Мутации флавивирусного белка оболочки, нарушающие разборку вириона
CY1122796T1 (el) Βελτιωμενες φαρμακοτεχνικες μορφες αδενοϊων
MX2018012166A (es) Dosificacion oral de compuestos peptido similar al glaucon-1 (glp-1).
UY34875A (es) Purificación de partículas tipo virus
IN2015DN03029A (ru)
PH12014501702A1 (en) Imidazopyrrolidinone compounds
PH12015501720B1 (en) Modulators of methyl modifying enzymes, compositions and uses thereof
JO3773B1 (ar) معدلات p2x7
AU2013225533A8 (en) Amido spirocyclic amide and sulfonamide derivatives
UY34674A (es) Cepa de flavobacterium plaguicida y composiciones bioactivas, metabolitos y usos
BR112015008272A2 (pt) cápsula para preparação de bebidas
IN2014DN08481A (ru)
MX2016008448A (es) Conjugados de var2csa-farmaco.
EA201590272A1 (ru) Пероральные дозированные формы для модифицированного высвобождения, содержащие руксолитиниб
UA116889C2 (uk) Фармацевтична композиція, що містить суміш ізоформ apg101 (cd95-fc)
AU2018253594A1 (en) Dihydroxyphenyl neurotransmitter compounds, compositions and methods
MY165075A (en) Pharmaceutical composition comprising fimasartan and hydrochlorothiazide
EA201590932A1 (ru) Композиции, содержащие вортиоксетин и донепезил
MX358132B (es) Solucion de trombina y metodos de uso de esta.
MX2015003034A (es) Jeringa que contiene una composicion, en particular farmaceutica, que comprende inmunoglobulinas, su metodo de fabricacion y uso.
UY34840A (es) Vacuna de virus de schmallenberg (sbv), métodos de producción y sus usos
UY34595A (es) Composición farmacéutica de liberación prolongada de trimetazidina
MX2020012953A (es) Usos del extracto de bacopa monnieri.
IN2013MU02732A (ru)
CL2012003733S1 (es) Botella